TNG.PA · Transgene SA

-

Please sign in to comment on TNG.PA

1 Comment

Admin

5 years, 4 months ago

Transgene SA is currently in a long term uptrend where the price is trading 1.2% above its 200 day moving average.

From a valuation standpoint, the stock is 87.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 35.5.

Transgene SA's total revenue sank by 0.0% to $4M since the same quarter in the previous year.

Its net income has dropped by 0.0% to $-2M since the same quarter in the previous year.

Finally, its free cash flow grew by 14.5% to $-7M since the same quarter in the previous year.

Based on the above factors, Transgene SA gets an overall score of 3/5.

ABOUT

Transgene SA

Transgene SA, a biotechnology company, designs and develops therapeutic vaccines and oncolytic viruses for the treatment of cancer in France. It involved in developing TG4050, a therapeutic vaccine that is in Phase II clinical trial for the treatment of head and neck cancers; TG4001, a therapeutic vaccine, which is in Phase II clinical trial for the treatment of human papillomavirus (HPV 16) positive cancers; and BT-001, an oncolytic virus, which is in Phase I/II clinical trial for the treatment of solid tumors. The company also develops TG6050 for the treatment of non-small cell lung cancer that is in Phase 1 clinical trial. It has strategic collaboration agreements with NEC Corporation and NEC Bio, BioInvent, Merck & Co., Inc., Oxford Biomedica, Stamford, SillaJen, and ProBioGen. The company was incorporated in 1979 and is headquartered in Illkirch-Graffenstaden, France. Transgene SA is a subsidiary of TSGH SAS.

TNG.PA · Transgene SA

-

Transgene SA

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Transgene SA using a moving average strategy